Personalis, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Personalis reported Q3 2026 revenue of $25.6M (vs. $14.5M in Q3 2025), driven by clinical test revenue of $4.4M (vs. $0.4M, up 1,000%) from 13,157 tests (vs. 4,388), population sequencing revenue of $4.1M (vs. $0.2M), and pharma services of $17.1M (vs. $13.1M). The company ended Q3 with $190.6M in cash. However, the company announced July 20, 2026 that it entered into a merger agreement with Tempus AI and will no longer provide guidance or hold earnings calls pending deal completion. Net loss widened to $33.8M in Q3 2026 vs. $21.7M in Q3 2025; nine-month net loss reached $95.5M.
Why this rating
Strong organic revenue growth (77% YoY) and clinical traction are positive, but pending merger uncertainty and widening losses offset optimism. Moderate materiality relative to $578M market cap.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.